The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors (Q40231262)

From Wikidata

Jump to navigation Jump to search

scientific article published on 22 March 2007

Language	Label	Description	Also known as
English	The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors	scientific article published on 22 March 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

author name string

Weisser M

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Haferlach C

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Hiddemann W

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Schnittger S

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

publication date

22 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1177-1182

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

21 January 2018

Real-time quantitative reverse transcription-polymerase chain reaction for the detection of AML1-MTG8 fusion transcripts in t(8;21)-positive acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

21 January 2018

New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

21 January 2018

Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

21 January 2018

Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

21 January 2018

Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

21 January 2018

Minimal residual core binding factor AMLs by real time quantitative PCR--initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

21 January 2018

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

21 January 2018

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

21 January 2018

Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

21 January 2018

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

21 January 2018

Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

21 January 2018

KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

21 January 2018

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

21 January 2018

Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

7 January 2021

based on heuristic

inferred from DOI database lookup

Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

7 January 2021

based on heuristic

inferred from DOI database lookup

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

7 January 2021

based on heuristic

inferred from DOI database lookup

Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404659

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2404659

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Dimensions Publication ID

0 references

release_durmkpfujbhmdpszmlwuz564gy

1 reference

https://api.fatcat.wiki/v0/release/durmkpfujbhmdpszmlwuz564gy

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40231262&oldid=2203519994"